Clinical TrialJun 17, 2026, 08:57 AM
Verastem RAMP 205 trial shows 86% 6-month OS in pancreatic cancer
AI Summary
Verastem announced positive updated safety and efficacy results from its RAMP 205 Phase 1b/2a trial for avutometinib plus defactinib in combination with standard-of-care chemotherapy in first-line metastatic pancreatic ductal carcinoma. The trial demonstrated an 86% overall survival rate at 6 months and a 52% objective response rate. Additionally, the company announced the dosing of the first patient in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, for KRAS G12D-mutated mPDAC.
Key Highlights
- RAMP 205 trial showed an 86% overall survival rate at 6 months.
- Progression-free survival rate at 6 months was 68%.
- Confirmed objective response rate was 52% (15/29 patients).
- 83% of patients experienced tumor shrinkage in the RP2D cohort of 29 patients.
- 9 patients remain on treatment in the RAMP 205 trial.
- First patient dosed in TARGET-D 201 Phase 2 trial for VS-7375.
Price Impact
More from VSTM